{"id":48080,"date":"2025-11-14T15:00:17","date_gmt":"2025-11-14T07:00:17","guid":{"rendered":"https:\/\/flcube.com\/?p=48080"},"modified":"2025-11-14T15:00:18","modified_gmt":"2025-11-14T07:00:18","slug":"corxel-secures-fda-ind-clearance-for-cx11-phase-2-trial-in-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48080","title":{"rendered":"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes"},"content":{"rendered":"\n<p><strong>Corxel Pharmaceuticals Limited<\/strong> announced today that the U.S. Food and Drug Administration (FDA) has <strong>cleared an Investigational New Drug (IND) application<\/strong> for a <strong>Phase\u202f2, multicenter, randomized, double\u2011blind, parallel\u2011group, placebo\u2011controlled study<\/strong> of its oral GLP\u20111 receptor agonist <strong>CX11 (VCT220)<\/strong> in patients with <strong>type\u202f2 diabetes mellitus (T2DM)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trial-design-amp-enrollment\">Trial Design &amp; Enrollment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Indication<\/strong><\/td><td>Type\u202f2 diabetes mellitus (T2DM)<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Adults on a stable metformin regimen \u00b1 a stable SGLT2\u2011inhibitor for \u2265\u202f90\u202fdays who have not achieved target glycemic control<\/td><\/tr><tr><td><strong>Sample size<\/strong><\/td><td>~\u202f350 participants (estimated)<\/td><\/tr><tr><td><strong>Arms<\/strong><\/td><td>CX11 (once\u2011daily oral) vs. matching placebo<\/td><\/tr><tr><td><strong>Primary endpoint<\/strong><\/td><td>Change in HbA1c from baseline at 24\u202fweeks<\/td><\/tr><tr><td><strong>Key secondary endpoints<\/strong><\/td><td>Fasting plasma glucose, body\u2011weight change, safety\/tolerability, incidence of hypoglycemia<\/td><\/tr><tr><td><strong>Start of enrollment<\/strong><\/td><td>Q1\u202f2026 (first\u2011quarter)<\/td><\/tr><tr><td><strong>Sites<\/strong><\/td><td>\u2265\u202f30 U.S. clinical sites, geographically diverse<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline\">Development Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>April\u202f14\u202f2025:<\/strong> FDA cleared a <strong>Phase\u202f2 obesity\/overweight trial<\/strong> of CX11 (first IND this year). First patient dosed\u202fJune\u202f16\u202f2025; topline results expected H1\u202f2026.<\/li>\n\n\n\n<li><strong>Nov\u202f13\u202f2025:<\/strong> FDA clears <strong>second Phase\u202f2 IND<\/strong> for CX11 in T2DM. Enrollment slated to begin Q1\u202f2026.<\/li>\n\n\n\n<li><strong>2027\u20112028:<\/strong> Planned <strong>Phase\u202f3 program<\/strong> to evaluate CX11 as a once\u2011daily oral alternative to injectable GLP\u20111 therapies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Oral GLP\u20111 breakthrough:<\/strong> CX11 is the <strong>first oral small\u2011molecule GLP\u20111 receptor agonist<\/strong> in Corxel\u2019s pipeline, aiming to capture patients who prefer pills over injections.<\/li>\n\n\n\n<li><strong>Market opportunity:<\/strong> The U.S. T2DM market exceeds <strong>$120\u202fbn<\/strong> in drug spend; oral GLP\u20111 agents could tap a <strong>~30\u202f%<\/strong> share of the injectable GLP\u20111 space, valued at <strong>\u2248\u202f$12\u202fbn<\/strong>.<\/li>\n\n\n\n<li><strong>IP &amp; rights:<\/strong> Corxel acquired <strong>global ex\u2011China rights<\/strong> to CX11 from <strong>Vincentage Pharma Co., Ltd.<\/strong> in December\u202f2024, securing full development control outside China.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-share-holder-impact\">Financial &amp; Share\u2011holder Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D spend:<\/strong> CX11 program expenses are projected at <strong>$45\u202fm<\/strong> for 2025\u20112026, funded primarily from cash on hand and a <strong>$75\u202fm<\/strong> revolving credit facility.<\/li>\n\n\n\n<li><strong>Share price reaction:<\/strong> Corxel shares opened <strong>+3.2\u202f%<\/strong> on the news, reflecting investor optimism about a differentiated oral GLP\u20111 candidate.<\/li>\n\n\n\n<li><strong>Future financing:<\/strong> Management indicated that <strong>no additional equity dilution<\/strong> is expected before Phase\u202f3 initiation, pending successful Phase\u202f2 read\u2011outs.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding the CX11 Phase\u202f2 trial, anticipated timelines, and market potential. Actual results may differ due to clinical outcomes, regulatory decisions, competitive dynamics, and other risks disclosed in Corxel\u2019s most recent Form\u202f10\u2011K and SEC filings.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,2471,39,4361],"class_list":["post-48080","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-corxel-pharmaceuticals","tag-diabetes","tag-hot-targets"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase\u202f2, multicenter, randomized, double\u2011blind, parallel\u2011group, placebo\u2011controlled study of its oral GLP\u20111 receptor agonist CX11 (VCT220) in patients with type\u202f2 diabetes mellitus (T2DM).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48080\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes\" \/>\n<meta property=\"og:description\" content=\"Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase\u202f2, multicenter, randomized, double\u2011blind, parallel\u2011group, placebo\u2011controlled study of its oral GLP\u20111 receptor agonist CX11 (VCT220) in patients with type\u202f2 diabetes mellitus (T2DM).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48080\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-14T07:00:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-14T07:00:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1304-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48080#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48080\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes\",\"datePublished\":\"2025-11-14T07:00:17+00:00\",\"dateModified\":\"2025-11-14T07:00:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48080\"},\"wordCount\":394,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48080#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1304-1.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CORXEL Pharmaceuticals\",\"Diabetes\",\"Hot targets\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48080#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48080\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48080\",\"name\":\"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48080#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48080#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1304-1.webp\",\"datePublished\":\"2025-11-14T07:00:17+00:00\",\"dateModified\":\"2025-11-14T07:00:18+00:00\",\"description\":\"Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase\u202f2, multicenter, randomized, double\u2011blind, parallel\u2011group, placebo\u2011controlled study of its oral GLP\u20111 receptor agonist CX11 (VCT220) in patients with type\u202f2 diabetes mellitus (T2DM).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48080#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48080\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48080#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1304-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1304-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48080#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","description":"Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase\u202f2, multicenter, randomized, double\u2011blind, parallel\u2011group, placebo\u2011controlled study of its oral GLP\u20111 receptor agonist CX11 (VCT220) in patients with type\u202f2 diabetes mellitus (T2DM).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48080","og_locale":"en_US","og_type":"article","og_title":"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes","og_description":"Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase\u202f2, multicenter, randomized, double\u2011blind, parallel\u2011group, placebo\u2011controlled study of its oral GLP\u20111 receptor agonist CX11 (VCT220) in patients with type\u202f2 diabetes mellitus (T2DM).","og_url":"https:\/\/flcube.com\/?p=48080","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-14T07:00:17+00:00","article_modified_time":"2025-11-14T07:00:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1304-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48080#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48080"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes","datePublished":"2025-11-14T07:00:17+00:00","dateModified":"2025-11-14T07:00:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48080"},"wordCount":394,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48080#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1304-1.webp","keywords":["Clinical trial approval \/ initiation","CORXEL Pharmaceuticals","Diabetes","Hot targets"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48080#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48080","url":"https:\/\/flcube.com\/?p=48080","name":"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48080#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48080#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1304-1.webp","datePublished":"2025-11-14T07:00:17+00:00","dateModified":"2025-11-14T07:00:18+00:00","description":"Corxel Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase\u202f2, multicenter, randomized, double\u2011blind, parallel\u2011group, placebo\u2011controlled study of its oral GLP\u20111 receptor agonist CX11 (VCT220) in patients with type\u202f2 diabetes mellitus (T2DM).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48080#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48080"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48080#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1304-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1304-1.webp","width":1080,"height":608,"caption":"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48080#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Corxel Secures FDA IND Clearance for CX11 Phase\u202f2 Trial in Type\u202f2 Diabetes"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1304-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48080"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48080\/revisions"}],"predecessor-version":[{"id":48082,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48080\/revisions\/48082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48081"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}